Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products

Last week, GW Pharmaceuticals PLC (NASDAQ:GWP) announced that Epidiolex, a cannabidiol oral medication for the treatment of seizures, is now available through a prescription in the US.

It is the first pharmaceutical formulation of a highly purified, plant-derived cannabidiol (CBD), a cannabinoid that lacks the high associated with marijuana, and is the first in a new category of anti-epileptic drugs. Epidiolex is an oral solution for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. The drug was approved by the Food and Drug Administration on June

...read more at https://www.proactiveinvestors.com/companies/news/208544/zynerba-pharmaceuticals-ceo-welcomes-fda-approval-of-cannabinoid-products-208544.html